Nuventra is pleased to announce the addition of Devin Welty, Ph.D. as Senior Consultant, Nonclinical & Clinical Pharmacology to its growing team of senior consultants. Dr. Welty has over 25 years’ experience in preclinical and clinical pharmacology leading organizations and projects teams from early discovery to approval and commercialization. Most recently he acted as the Global Head of DMPK, Shire.
“Devin is an exciting addition to Nuventra’s team of drug development experts,” says Geoffrey Banks, Nuventra’s CEO. “His robust experience in preclinical and clinical pharmacology will serve as a strong resource for our new and existing clients.”
Dr. Welty has supported the successful submission of more than 50 IND/CTAs and more than 20 NDA/MAA/BLAs for small molecules, biologics and gene therapy therapeutics. He has extensive experience in pharmacokinetics, pharmacodynamics and systems pharmacology and adopting model-informed approaches for candidate nomination and efficient clinical development strategy.
His therapeutic area experience includes neurology, ophthalmology for anterior and posterior retinal diseases, and rare disease therapeutics including lysosomal storage diseases, hereditary angioedema, short-bowel syndrome and hemophilia.